In addition, the rate of recurrence was reportedly lower in patients with BRCA1/2 mutations in triple-negative breast cancer patients [29], and prognosis was poor when expression level of BRCA1 was high in sporadic epithelial ovarian cancer patients [30]. The gene discussed is BRCA1; the disease is triple-negative breast carcinoma.